Skip to main content

Table 1 Basal clinicopathologic characteristics in training and validation cohort

From: A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy

 

Training set

Validation set

 

Characters

n = 410(%)

n = 148(%)

P

Sex

 Male

327(79.8)

124 (83.8)

0.286

 Female

83 (20.2)

24 (16.2)

 

Age

 <50

91 (22.2)

25 (16.9)

0.173

  ≥ 50

319 (77.8)

123 (83.1)

 

Tumor size(cm)

 <3

230 (56.1)

84 (56.8)

0.212

 3–5

81 (19.8)

37 (25.0)

 

  ≥ 5

99 (24.1)

27 (18.2)

 

Tumor multiplicity

 Single

266 (64.9)

77 (52.0)

0.006

 Multiple

144 (35.1)

71 (48.0)

 

Cirrhosis

 Yes

377 (92.0)

135 (91.2)

0.780

 No

33 (8.0)

13 (8.8)

 

PVTT

 Yes

145 (35.4)

40 (27.0)

0.065

 N0

265 (64.6)

108 (73.0)

 

Ascites

 Yes

162 (39.5)

53 (35.8)

0.428

 No

248 (60.5)

95 (64.2)

 

HBsAg

 Positive

330 (78.5)

120 (81.1)

0.876

 Negative

80 (21.5)

28 (18.9)

 

NLR

 <5

344 (83.9)

132 (89.2)

0.119

  ≥ 5

66 (16.1)

16 (10.8)

 

HGB(g/L)

 <120

159 (38.8)

58 (39.2)

0.930

  ≥ 120

251 (61.2)

90 (60.8)

 

PLT(*10^9/L)

 <100

219 (53.4)

80 (54.1)

0.894

  ≥ 100

191 (46.6)

68 (45.9)

 

CR (μmoI/L)

 <111

391 (95.4)

141 (95.3)

0.962

  ≥ 111

19 (4.6)

7 (4.7)

 

ALT(U/L)

 <50

347 (84.6)

130 (87.8)

0.343

  ≥ 50

63 (15.4)

18 (12.2)

 

AST(U/L)

 <40

268 (65.4)

113 (76.4)

0.014

  ≥ 40

142 (34.6)

35 (23.6)

 

TBIL (μmol/L)

 <18.8

218 (53.2)

87 (58.8)

0.240

  ≥ 18.8

192 (46.8)

61 (41.2)

 

ALB(g/L)

  < 40

275 (67.1)

103 (69.6)

0.574

  ≥ 40

135 (32.9)

45 (30.4)

 

LDH(U/L)

 <250

365 (89.0)

131 (88.5)

0.865

  ≥ 250

45 (11.0)

17 (11.5)

 

GGT (U/L)

 <60

273 (66.1)

99 (66.9)

0.861

  ≥ 60

139 (33.9)

49 (33.1)

 

PTA (%)

  < 70

142 (34.6)

42 (28.4)

0.165

  ≥ 70

268 (65.4)

106 (71.6)

 

CEA (ng/ml)

  < 5

345 (84.1)

113 (76.4)

0.034

  ≥ 5

65 (15.9)

35 (23.6)

 

CA199(u/ml)

  < 37

364 (89.3)

133 (90.5)

0.664

  ≥ 37

44 (11.7)

14 (9.5)

 

CRP (mg/L)

  < 5

266 (64.9)

99 (71.2)

0.180

  ≥ 5

144 (35.1)

40 (28.8)

 

Child-Pugh

 A

230 (56.1)

92 (62.2)

0.168

 B

127 (31.0)

45 (30.4)

 

 C

53 (12.9)

11 (7.4)

 

BCLC stage

 0-B

322 (78.5)

119 (80.4)

0.632

 C-D

88 (21.5)

29 (19.6)

 

ALBI grade

 I

149 (36.3)

76 (51.4)

0.004

 II

207 (50.5)

59 (39.9)

 

 III

56 (13.7)

13 (8.8)

 

TNM

 I

159 (38.8)

53 (35.8)

0.005

 II

66 (16.1)

42 (28.4)

 

 III

131 (32.0)

43 (29.1)

 

 IV

54 (13.2)

10 (6.8)

Â